Ordinary Rebalance | Solactive Obesity Index | Effective Date 1st February 2023
In the ordinary rebalance, the following index composition will be implemented effective open 01.02.2023:
ADAPTHEALTH CORP |
ALTIMMUNE INC |
ANGIODYNAMICS INC |
ARTIVION INC |
BIONIME CORP |
CARDIOVASCULAR SYSTEMS INC |
CATO CORP-CLASS A |
CVRX INC |
DARIOHEALTH CORP |
DEXCOM INC |
EKF DIAGNOSTICS HOLDINGS PLC |
ESPERION THERAPEUTICS INC |
FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED |
HERBALIFE NUTRITION LTD |
HUA MEDICINE |
I-SENS INC |
INSPIRE MEDICAL SYSTEMS INC |
INSULET CORP |
IRHYTHM TECHNOLOGIES INC |
LEMAITRE VASCULAR INC |
LEXICON PHARMACEUTICALS INC |
LIFETECH SCIENTIFIC CORP |
MADRIGAL PHARMACEUTICALS INC |
MANNKIND CORP |
MEDIFAST INC |
MICROPORT SCIENTIFIC CORP |
N BROWN GROUP PLC |
NIPRO (NISSHO) CORP ORD |
NOVAREX CO LTD |
NOVO NORDISK A/S |
RESMED INC-CDI |
RHYTHM PHARMACEUTICALS INC |
SD BIOSENSOR INC |
SENSEONICS HOLDINGS INC |
TAIDOC TECHNOLOGY CORP |
TANDEM DIABETES CARE INC |
TCI CO LTD |
TEVA PHARMACEUTICAL IND LTD |
USANA HEALTH SCIENCES INC |
WW INTERNATIONAL INC |